Arcturus Therapeutics Holdings (ARCT) Prepaid Assets (2018 - 2026)
Arcturus Therapeutics Holdings' (ARCT) quarterly Prepaid Assets came in at $4.2 million in Q1 2026, down 52.54% YoY from $8.8 million in Q1 2025, and down 16.27% on a QoQ basis from $5.0 million in Q4 2025.
Analysis
Arcturus Therapeutics Holdings (ARCT) Prepaid Assets (2018 - 2026) Analysis & Trends
Arcturus Therapeutics Holdings (ARCT) has 9 years of Prepaid Assets data on file, last reported at $4.2 million in Q1 2026.
- Quarterly Prepaid Assets fell 52.54% year-over-year to $4.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $4.2 million (down 52.54% YoY) and the FY2025 annual result came in at $5.0 million, down 50.16% from the prior year.
- Prepaid Assets slipped to $4.2 million in Q1 2026, from $5.0 million in the prior quarter.
- In the past five years, Prepaid Assets ranged from a high of $10.0 million in Q4 2024 to a low of $3.6 million in Q1 2022.
- A 5-year average of $6.5 million and a median of $5.9 million in 2025 frame the typical range for Prepaid Assets.
- Annual changes were most pronounced in 2022 — Prepaid Assets jumped 216.17% — and 2026, when it sank 52.54%.
- Tracing ARCT's Prepaid Assets over 5 years: stood at $8.7 million in 2022, then fell by 13.41% to $7.5 million in 2023, then surged by 32.66% to $10.0 million in 2024, then slumped by 50.16% to $5.0 million in 2025, then dropped by 16.27% to $4.2 million in 2026.
- The last three Prepaid Assets figures came in at $4.2 million (Q1 2026), $5.0 million (Q4 2025), and $5.9 million (Q3 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn |
| 10 | Arcturus Therapeutics Holdings | 449.65 Mn | 258.17 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 3.87 Mn |
| Mar 31, 2026 | 4.16 Mn |
| Dec 31, 2025 | 4.97 Mn |
| Sep 30, 2025 | 5.89 Mn |
| Jun 30, 2025 | 5.83 Mn |
| Mar 31, 2025 | 8.77 Mn |
| Dec 31, 2024 | 9.98 Mn |
| Sep 30, 2024 | 8.44 Mn |
| Jun 30, 2024 | 7.59 Mn |
| Mar 31, 2024 | 5.34 Mn |
| Dec 31, 2023 | 7.52 Mn |
| Sep 30, 2023 | 8.13 Mn |
| Jun 30, 2023 | 3.97 Mn |
| Mar 31, 2023 | 4.14 Mn |
| Dec 31, 2022 | 8.69 Mn |
| Sep 30, 2022 | 6.96 Mn |
| Jun 30, 2022 | 5.77 Mn |
| Mar 31, 2022 | 3.64 Mn |
| Dec 31, 2021 | 5.10 Mn |
| Sep 30, 2021 | 5.07 Mn |